FDA grants breakthrough device designation to new chronic venous insufficiency device

Anthony Vecchione | | Cardiovascular Business | Vascular & Endovascular

Hancock Jaffee Laboratories, a California-based healthcare technology company focused on cardiac and vascular conditions, has received the FDA’s breakthrough device designation for its VenoValve device for chronic venous insufficiency.

The company's first-in-human study, shared with the public in December 2020, found that VenoValve was associated with significant improvements in reflux, disease manifestations and pain following surgery. In addition, there were no material adverse events 30 days after implantation.

The company is now planning a new clinical trial, SAVVE U.S., that will enroll up to 75 patients. Enrollment should begin within the next 60 days.

"We are very pleased to have the opportunity to work with the FDA on an expedited basis as we try to bring relief to the millions of patients who suffer from deep venous CVI and who currently have no effective treatment options," Hancock Jaffe CEO Robert Berman said in a prepared statement. "The VenoValve significantly improved the lives of the patients in our first-in-human study, and we hope to replicate that success in our SAVVE U.S. clinical trial."

Anthony Vecchione

Related Content

IVUS-guided PCI reduces risks in patients with diabetes
LAAC with Watchman FLX reduces bleeding risks after AFib ablation
Bioresorbable BTK stent superior to ballon angioplasty at 2 years
Shockwave Medical’s IVL technology delivers more positive outcomes for PAD patients
Standing desks fail to lower blood pressure or minimize heart risks—they may even do damage
IVL vs. RA for chronic total occlusion PCI: Key data cardiologists should know

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."